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Abstract
Electroporation is a well-known phenomenon that occurs at the cell membrane when cells are exposed to high-intensity electric
pulses. Depending on electric pulse amplitude and number of pulses, applied electroporation can be reversible with membrane
permeability recovery or irreversible. Reversible electroporation is used to introduce drugs or genetic material into the cell
without affecting cell viability. Electrochemotherapy refers to a combined treatment: electroporation and drug injection to
enhance its cytotoxic effect up to 1000-fold for bleomycin. Since several years, electrochemotherapy is gaining popularity as
minimally invasive oncologic treatment. The adoption of electrochemotherapy procedure in interventional oncology poses
several unsolved questions, since suitable tumor histology and size as well as therapeutic efficacy still needs to be deepen.
Electrochemotherapy is usually applied in palliative settings for the treatment of patients with unresectable tumors to relieve pain
and ameliorate quality of life. In most cases, it is used in the treatment of advanced stages of neoplasia when radical surgical
treatment is not possible (eg, due to lesion location, size, and/or number). Further, electrochemotherapy allows treating tumor
nodules in the proximity of important structures like vessels and nerves as the treatment does not involve tissue heating. Overall,
the safety profile of electrochemotherapy is favorable. Most of the observed adverse events are local and transient, moderate
local pain, erythema, edema, and muscle contractions during electroporation. The aim of this article is to review the recent
published clinical experiences of electrochemotherapy use in deep-seated tumors with particular focus on liver cases. The
principle of electrochemotherapy as well as the application to cutaneous metastases is briefly described. A short insight in the
treatment of bone metastases, unresectable pancreas cancer, and soft tissue sarcoma will be given. Preclinical and clinical studies
on treatment efficacy with electrochemotherapy of hepatic lesions and safety of the procedure adopted are discussed.
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Introduction
Electrochemotherapy (ECT) is a locally enhanced chemother-
apy that combines the administration of chemotherapeutic
drugs with well-dosed electric pulses for cell membrane elec-
troporation (EP). In 1957, scientists discovered the influence of
electric fields on axons and cell membranes.1-3 The exposure of
biological membranes to a sufficiently high external electric
field can lead to a rapid and large increase in electric
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conductivity and permeability, called membrane EP. While
applying an electric field on cell membranes, their surface
tension will be destabilized and nonpermanent molecules can
diffuse into the cytosol. According to the theory of aqueous
pore formation, pores are able to form spontaneously, when the
bilayer is exposed to an electrical field (>50 V).4,5 It is assumed
that the induced voltage causes lipid molecule rearrangement
on the bilayer that supports pore formation.4,6,7 Even with
modern molecular dynamic simulation software, the pore for-
mation of electric stimulated membranes is not completely
understood. Thus, the presumed pore formation caused by EP
has not yet been observed directly, possibly due to the micro-
scale dimension and fragile structure of pores and cells.
When electric pulses are applied to cells, 2 different phe-
nomena are observed: reversible EP and irreversible electro-
poration (IRE), both used in clinical practice. Reversible EP
will increase cell membrane permeability and open an access
route for molecules that are too big to cross the cell membrane
(DNA, RNA) or facilitates cell enter by hydrophilic molecules
(bleomycin [BLM], cisplatin).8-10 These molecules once
crossed the cell membrane exert their effect in the resealing
and intact cells. In contrast, IRE (>600 V/cm) is used as non-
thermal form of soft tissue ablation in clinical routine.11 The
IRE of cell membranes leads to a disturbance of the cell home-
ostasis and thus ultimately to apoptosis in the treated tissue.
This method of tissue ablation has found widespread use to
destroy malignant tissue.12-14
As the application of ECT in the case of cutaneous tumors is
widespread adapted in clinical routine, only a brief outline will
be given. The main focus of this review is set on the treatment
of deep-seated tumors, especially hepatic metastases, as this
approach offers new and interesting treatment options in the
case of liver cancer. Moreover, research in animal models as
well as current human studies is presented and possible use in
clinical practice is discussed.
Principle of ECT
The concept of ECT is based on the aforementioned properties
of reversible EP combined with therapeutic efficacy of che-
motherapeutic agents. Due to the increased permeability of the
cell membrane, chemotherapeutic agents can pass into cells
and induce cell death mitosis in the targeted tissue. In general,
a patient receiving ECT treatment will first get an intravenous
or intratumoral administration of an anticancer drug (eg, BLM,
cisplatin) so it can evenly distribute over the vascular system
and extracellular space of the tissue. Electrodes located around
or inside the tumor will deliver defined electric pulses which
enables diffusion of otherwise membrane nonpermeant antic-
ancer drug into the target cells (Figure 1). After a short time, a
few seconds to several minutes after exposure to the electric
field, the membrane permeability will return to its initial state
and the specific chemotherapeutics will cause multiple DNA
breaks (BLM) or intra- and inter-strand DNA bonds (cisplatin)
in the abnormal tumor cells. Benefits arising from this combi-
nation therapy include a low dose of cytostatic drug due to
locally increased cytotoxic effect (BLM, 1000-fold and cispla-
tin, 80-fold increase of toxicity),15-17 as only a few molecules
per cell are needed to induce cell death during a single treat-
ment session. Another effect caused by the treatment is the
release of intact tumor antigens due to substance shedding by
the damaged cells. Released tumor antigens are exposed to the
immune system of patients and activate tumor antigen-directed
immune response. Since ECT is a local treatment, distant
Figure 1. An 88-year-old male patient receiving hepatic ECT treatment. A, Percutaneous placement of electrode needles for hepatic lesion
treatment. B, Preinterventional CT imaging of hepatic metastasis (white arrowhead; IV liver segment). C, Control CT imaging during electrode
needle placement. CT indicates computed tomography; ECT indicates electrochemotherapy.
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metastases should not be affected.8,18 Nevertheless, the treat-
ment of tumor nodules with ECT recruiting components of the
immune system may elicit a systemic immune response against
distant metastases: abscopal effect.19,20 Furthermore, a vascu-
lar disruption and hypoperfusion caused by EP (vascular lock)
can be observed during intervention. This effect has been
attributed to electrical-induced reflexive constriction of arter-
ioles and interstitial edema of endothelial structures.21 A
decreased blood flow can be observed in the treated areal which
increases drug retaining time as well as prevents bleeding of
treated well-vascularized organs.22 The synergistic effects of
immune checkpoint inhibitory therapy can achieve a further
stimulation of the antitumor immune response.23
Application Area of ECT
The efficacy of ECT treatment is well demonstrated for cuta-
neous and subcutaneous melanomas, and the technique can be
applied in a variety of malignant lesions.24,25 Also, patients
with diabetes as comorbidity or pretreated by surgery, radio-
frequency ablation (RFA), or transarterial chemoembolization
(TACE) can be treated by ECT.26 The range of applications can
be divided into 3 groups: (1) treatment of cutaneous and sub-
cutaneous metastases located in head or neck, melanoma, non-
melanoma skin cancer, or breast cancer metastases to the
skin8,24,27-30; (2) treatment of noncutaneous metastases located
in bone, liver, or soft tissue sarcoma (STS)31-33; and (3) clinical
trials for the treatment of primary tumors, such as ovary or
colon cancer.34,35
Although there seems to be no restrictions in the application
by various malignant lesions, some limitations still occur. For
individual tissues, variable specific treatment protocols are
available. Also, different lesions need special shaped electro-
des or numbers of electrodes as well as individual pulse gen-
erators.36 The successful ECT performance is also depended on
tumor size and location. The drug perfusion of large metastases
may be insufficient and lead to decreased drug concentration in
the inner portion and impede the drug cytotoxic effect.37 Also,
large metastases will show low concentration of the drug at the
time of EP due to delayed drug perfusion.38 In the case of big
metastases, correct needle placement in order to ensure an
effective and homogeneous coverage with the electric field is
mandatory.39,40 As there are many variables that individually
need to be taken into account for each tumor, a general protocol
can be hardly designed. Also, the time of response can vary
depending on the size and location,41 which impedes a consis-
tent follow-up evaluation schedule. Repetitive ECT interven-
tion showed to influence the treatment result in a positive
way.30 Nevertheless, patients treated with ECT show fewer
side effects than patients treated with systemic chemotherapy.
In addition, ECT can be applied as adjuvant therapy.
Factors affecting ECT effectiveness include tumor size,
previous treatments, location, and histotype. Cutaneous
metastases smaller than 3 cm, not preirradiated, show the best
objective response rate. Moreover, electrode geometry, num-
ber, and separation will affect the electric field in the tumor as
well as the treatment outcome. However, cell homeostasis can
be disturbed permanently if certain thresholds are exceeded.
Critical factors are among others especially amplitude and
pulse duration. If duration or amplitude of electric pulses
is increased, irreversible disruption of cell homeostasis
will happen (reversible EP: eg, 1.3 kV/cm, 99 ms; IRE: eg,
1.5 kV/cm, 300 ms).12,42
Assisting and Supporting Tools During ECT
Correct spatial individual long-needle positioning needs skills
and the support of intraoperative imaging: X-ray, ultrasound, or
computed tomography (CT) imaging. Specific instruments
have been developed to guide needle insertion (navigation sys-
tems) and positioning and to guarantee the complete and homo-
genous coverage of the tumor volume by the applied electric
field. Moreover, treatment needs to be carefully planned with
software that indicates where to position electrodes and the
required electric field conditions.43 Dedicated EP preoperative
planning tools were developed. To help the surgeon, the soft-
ware called PULSAR (PULSUR ver. 1.0) was realized by with
the functionality to calculate an optimized placement of the
electrodes within or around a predefined area segmented by
the user. The software estimates the coverage of the electric
field and minimizes the number of electrodes required. The tool
provides an estimation of the electric field in the region of
interest selected by expert operators by means of approximate
calculations giving indication of electrodes configuration, vol-
tage, and distance for each couple of electrodes.
Another software proposed in literature43 was a web-based
tool that automatically builds a 3-D model of the target tissue
from the medical images uploaded by the user and then uses
this 3-D model to optimize treatment parameters. In addition,
this web-based tool is intended to facilitate the treatment plan-
ning process and reduce the time needed for it. It is crucial for
facilitating expansion of EP-based treatments in clinical prac-
tice and ensuring reliable treatment for the patients.
Also keeping a safety margin while needle placement helps
to treat the tumor and the tumor margin to prevent possible
tumor cell infiltrating normal tissue. This can be ensured by
navigated needle placement and confirmed by ultrasound or CT
imaging. As helpful tool, navigation systems can be applied
additionally. Navigation systems can be separated into 2
groups, “robotic”-assisted needle placement and electrode
tracking systems.44-46 During intervention, the integration of
these systems decreases the probability of needle repositioning
and increases the probability to accurately fit the needle posi-
tion according to the treatment plan. Nevertheless, control ima-
ging complements this, as the needle position can be visually
tracked and compared to the treatment plan. So the integration
of software tools for simulation of local electric field distribu-
tion, image guidance (CT, ultrasound) during electrode posi-
tioning, and navigation systems for needle insertion will
increase accuracy, decrease intervention times, and ensure
probe positioning.44,47
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Electrochemotherapy in Clinical Practice
Electrochemotherapy of Cutaneous and
Subcutaneous Metastases
Electrochemotherapy treatment of superficial (ie, skin and sub-
cutaneous) neoplastic lesions regardless of their histology is
well established.30,48-54
Electrochemotherapy has been adopted for the treatment of
skin metastases of squamous cell carcinoma, melanoma, basal
cell carcinoma, adenocarcinomas (of the breast, salivary
glands, and kidneys), Kaposi sarcoma, Merkel cell carcinoma,
transitional cell carcinoma of the urinary bladder, and head and
neck cancer. It can be considered when there is no possibility of
surgical intervention, when surgery is contraindicated or would
be too harming, and when addressing lesions resistant to che-
motherapy and radiotherapy. A thorough discussion of these
modalities can be found elsewhere in the literature.25,36,55 In a
10-year audit, the effect of ECT in the case of cutaneous breast
cancer was analyzed. The authors proposed to apply ECT as an
early treatment modality, as the treatment response seems to be
influenced by the lesion size and a good response can be
obtained (objective response 79.7%).56 Several clinical studies
as well as the European Standard Operating Procedures for
Electrochemotherapy and Electrogenetherapy (ESOPE) project
have set up defined standard operating procedures in order to
ensure patient safety and to achieve optimal treatment of cuta-
neous and subcutaneous metastases. These recommendations
include chemotherapeutic drugs, drug delivery route, electrode
shape, and pulse parameters as well as tumor properties (mea-
surement, location, and number).41 Reports from clinical
experiences adopting the operating procedures of the ESOPE
study were consistent with those of controlled clinical trials.
The meta-analysis of Mali et al,25 which included 44 studies
involving 1894 tumors, reported an objective response rate to
ECT of 84%. When ECT procedures are performed according
to these recommendations, an objective response rate of 68% to
86% and complete response rate of 33% to 60% of treated
malignant melanoma nodules were observed. Dependent on
tumor size, the therapy outcome varies whereas tumors smaller
than 3 cm show the highest response rates.38 Due to the treat-
ment, temporary flushing, fluid accumulation, and swelling
may occur as side effects.24,57,58 In their study on ECT (BLM
followed by EP) in 85 patients, Campana et al59 showed that
tumor size and number of lesions are significant predictive
factors for response. An increasing number of electrode appli-
cations and ECT cycles were predictors of local control. There
were no predictors of toxicity.
According to Bertino et al,58 in a recent clinical trial on skin
cancer of the head and neck, better responses are obtained with
small lesions (3 cm), primary tumors, and naive tumors. Pre-
vious surgery least affected the outcome compared to (che-
mo)radiotherapy or multiple treatments of recurrent tumor
nodules. They reported that no ECT-related serious adverse
events were observed and the most common adverse events
were postoperative pain (92%) and skin reactions (18%) that
decreased over time.
Recently, Kunte et al,60 in a prospective cohort study by
InsPECT, experienced an objective response of 74% in 151
patients with metastatic melanoma, and 229 of 394 treated
lesions showed a complete response of 58%. One-year overall
survival was 67%, while melanoma-specific survival was 74%.
Caraco et al61 reported that 44.8% of complete responders
experienced a long-lasting response after 1 ECT session and
were disease-free after a mean duration of follow-up of 27.5
months.
Multiple clinical experiences report preliminary data on the
safety and the benefit of the ECT and target therapy combina-
tions.62-66 In clinical practice, ECT is successfully used for the
treatment of cutaneous and subcutaneous tumors and receives
satisfying results treating melanoma. Current research aims
now to identify the best treatment conditions and guidelines
in order to treat deep-seated tumors.32,67
Electrochemotherapy of Noncutaneous
Deep-Seated Tumors
As stated by Miklavcic et al,39 efforts to translate the applica-
tion of ECT from easily accessible lesions (eg, cutaneous
metastasis of different malignancies) to the treatment of non-
superficial tumors require addressing the critical importance of
achieving complete EP of the target lesion(s). The preliminary
results of the published studies on these new clinical indica-
tions show that the treatment of metastases of deep-seated
tumors is feasible and safe. Electrochemotherapy is effective
in resolution or regression of tumor nodules and quality of life
of patients is improved.68
Locally advanced pancreatic cancer
Preclinical experiences. Electrochemotherapy in pancreatic
cancer has been investigated by Jaroszeski et al69 in a precli-
nical trial using a hamster animal model. The combination of
EP with intratumoral BLM was able to induce a 25% response
rate in hamster in which tumoral cells were injected directly
into pancreas. In vivo effects of EP were evaluated by Girelli
et al70 in normal pancreas of the rabbits. The EP has shown to
be a valid alternative for the local control of nonresectable
pancreatic cancer because the procedure did not affect pancrea-
tic parenchyma.
Clinical experience. A prospective clinical phase I/II study to
evaluate feasibility, safety, and efficacy of ECT by means of
VGP02 Cliniporator model was published by Granata et al71
and reported encouraging results. No acute (intraoperative)
and/or postoperative serious adverse events related to ECT
were observed; no clinically significant electrocardiographic,
hemodynamic, or serum biologic changes were noted. No clini-
cally relevant elevation in amylase or lipase levels was
observed in any patient and no bleeding or damage to surround-
ing viscera occurs. Functional imaging based on magnetic reso-
nance imaging (MRI) and positron emission tomography scan
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demonstrated to be more suitable to evaluate ECT response in
patients with locally advanced pancreatic adenocarcinoma than
CT imaging. According to the authors, ECT of locally
advanced pancreatic adenocarcinoma is feasible, safe, and
effective treatment modality.71,72 Clinical study is currently
in progress, and ECT using variable geometry technology will
be used to treat all patients who will be enrolled starting from
this time.
Bone metastasis. Bone metastases are common disabling com-
plications in patients with cancer that impair general health
status, quality of life, and survival. Pain relief is one of the
most challenging and significant problems in the management
of these patients. Many treatments are available for the pallia-
tive management of patients with metastatic bone disease,
including radiotherapy, thermal and cryoablation, high-
intensity-focused ultrasound, resection, and the application of
bone cement to fill osteolytic areas. When the surgical removal
or ablation of metastases is not indicated (unresectable bones
such as pelvis, vertebral bodies, or in case of disseminated
disease), the use of narcotics for pain relief and of local ablative
techniques such as RFA or selective embolization can be cho-
sen even if these treatments are not always effective.
Electrochemotherapy is a local treatment modality charac-
terized by minimal invasiveness, is completed in short time and
absence of severe adverse events compared to other palliative
surgical procedures, and characterized by repeated irradiation,
hyperthermia, or isolated limb perfusion or infusion. Minimally
invasive approach to bone metastases treatment with ECT,
using variable geometry and Cliniporator VITAE (IGEA
S.p.A., Carpi, Italy) and BLM, was performed for the first time
in Bologna.
Preclinical studies with ECT. A preclinical study on 10.5-
month-old New Zealand White rabbits was performed by Fini
et al.31 The study was designed to prove that EP was effective
in cell ablation also in the presence of a mineralized matrix. An
appropriate combination of voltage and electric pulses induced
ablation of bone cells without affecting bone mechanical com-
petence and the recovery of osteogenic activity that was com-
pletely recovered by 30 days after EP. Electrochemotherapy
was used to control bone osteolysis induced in rat tibia by
injection of syngeneic breast cancer cells. Bone resorption and
tibia fracture were prevented in all animals by one single treat-
ment with ECT.31 Furthermore, in animal treated with ECT,
trabeculae maintained a normal structure and morphology.
Overall, preclinical investigation provides the rational bases
to investigate ECT in the treatment of human bone metastasis.
Clinical experience. After preclinical studies that demon-
strated bone osteogenic activity and bone hardness to be pre-
served after ECT, a phase I–II clinical trial has been
conducted at Instituto Ortopedico Rizzoli (Bologna, Italy) in
order to assess safety and feasibility of ECT on bone metas-
tases. No complications were reported, and fast recovery was
observed in patients with impending or actual fracture of the
treated bone.73,74
After primary staging (bone scan, CT/MRI, etc), 10 patients
affected by bone metastases of the appendicular skeleton were
treated with ECT according to ESOPE method. Nine more
patients with pelvic or sacral metastases were treated under
CT guidance “out of protocol.” The procedure was performed
in general anesthesia, and the patient was discharged the day
after the treatment. The ECT response was assessed by either
MRI or CT imaging 4 and 8 weeks after ECT. Early results
show pain relief in 56% of the patients with quality of life
improvement. In few patients, radiographic response was also
observed with necrosis of the metastatic lesion. Although these
early clinical results are promising, a longer follow-up and
larger cohort of patients are warranted.
A phase II clinical study with ECT was conducted on 29
patients affected by painful bone metastases. The appendicular
skeleton was affected in 15 patients, while in 14 patients, other
sites were involved. All patients well tolerated the procedure,
and no intraoperative or postoperative complications were
observed. At a mean follow-up of 7 months, 24 patients were
available for evaluation. Patients affected by bone metastases
obtained an improvement of pain (50%) in 84% of the cases
after ECT. Results reported in this study demonstrated ECT to
be safe and feasible in the treatment of painful bone metastases
even when other previous treatments were ineffective.74
Case Report
A case report of a spine metastasis treated during open surgery
was reported.75 Mini-open surgery with a left L5 laminectomy
was performed under general anesthesia to introduce the elec-
trodes. The assessed follow-up period was 48 months after the
ECT procedure. Neither serious ECT-related adverse events
nor BLM toxicity were reported. The patient obtained an excel-
lent improvement in pain intensity. The experience gathered in
the treatment of bone metastases allowed to prepare specific
guidelines adopted by Societa` Italiana Ortopedia e Traumato-
logia and Associazione Italiana Oncologia Medica.76
Nonsuperficial large soft tissue tumors. Preliminary results of
“Phase I/II study of ECT using variable geometry poration
(VGP) and bleomycin for the treatment of deep and large soft
tissue tumors” have been presented at the European Society for
Medical Oncology (ESMO) Conference 2014.
An ex vivo study on surgical specimen was performed to
explore the difference in tissue electrical properties of STS.
These results may be used to verify whether tuning electric
field intensity according to the specific STS histotype could
improve tissue EP and ultimately treatment efficacy.77,78
Liver metastases. Since the liver is an organ of particular current
research interests in ECT, results of preclinical studies and
clinical experiences will be given in more detail. Besides estab-
lished ablation modalities like microwave ablation79 or RFA80
and IRE,81 there is need for a controlled nonthermal ablation
modality that enhances the efficacy of chemotherapeutic
agents. The benefit of nonthermal ablation, like IRE, is the
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ability to treat lesions without thermonecrosis. This enables the
ability to ablate near-sensitive structures like vessels and
nerves, as no heat will be produced which spread around the
treated area. An already established locoregional method is
TACE. During TACE, embolizing agents and chemotherapeu-
tics will be administrated via catheter to obtain tissue-specific
necrosis. In cases of hepatocellular carcinoma (HCC), a com-
plete response of 23% and objective response of 66% as well as
an improvement in survival can be observed after TACE.82,83
When treating malignant liver metastases, a partial response
rate up to 56% in the case of liver metastasis with neuroendo-
crine tumors (stable disease 40%),84 partial response up to
11.5% in the case of liver metastases from pancreatic cancer
(stable disease 78%),85 and partial response up to 80% in the
case of colorectal liver metastases (stable disease up to 48%)86
were reported. As both therapy concepts are based on locore-
gional application of cytostatic in hepatocellular parenchyma, a
similar response rate of ECT by liver lesions can be possible.
Similar to TACE, ECT allows for a controlled locoregional
additional chemotherapy without marked systemic side effects.
As the chemotherapeutics applied during ECT are membrane
impermeant, even better results might be possible. The estab-
lishment and expansion of ECT in deep-seated tumors (eg,
liver, bone metastases) will open up new opportunities for
minimally invasive treatment of metastases and carcinomas.
Electrochemotherapy of hepatic tumors
Electrochemotherapy in animal trial. First trials of ECT by
hepatic tumors were conducted in animal models (Table 1).
Electrochemotherapy was shown to be effective to reduce the
volume of hepatic metastases of colorectal cancer in the rats.88
The first study of the effects of ECT on tumors transplanted to
livers in rabbits was conducted by Ramirez et al.90 Almost
complete tumor necrosis was observed after ECT, resulting
from both BLM direct cytotoxic effects on electropermeabi-
lized tumor cells and indirect effects on the tumor vessels. A
large reduction in tumor growth rate and significantly longer
survival times were scored in comparison with control rabbits.
Moreover, ECT of liver tumors was well tolerated and devoid
of systemic side effects.
Jaroszeski et al reported first results of ECT in rats with
induced hepatic tumor growth by injection of N1S1 rat hepa-
toma cells. Animals treated with cytostatic and electrical pulses
showed a significantly better response (69% complete
response; 15% partial response) to the treatment than the con-
trol groups (EP only; BLM only; no treatment).87 In a follow-
ing study,89 the effect of ECT on normal liver tissue was
analyzed in a rat model. Treatment with electric pulses higher
than 1500 V/cm resulted in slightly elevated levels of necrosis,
whereas lower amplitudes showed no remarkable effects. The
combined application of BLM (0.5 U) and electric pulses
showed, in cases treated with 1500 to 2250 V/cm, 1.5% and
20% to 30% necrosis of the treated area, whereas lower ampli-
tudes caused almost no necrosis. Low levels or no necrosis
were observable 56 days after ECT.
As the duration and intensity of the electrical pulse deter-
mines whether EP is reversible or irreversible, measuring of the
passive electrical properties of electroporated tissues may pro-
vide a quality assurance and real-time feedback on the ECT
process. However, tests revealed that the overall long-term
pattern of change in conductivity in hepatic cells after EP is
complex and differs between reversible EP and IRE.95
Electrochemotherapy in Human Clinical Trial. Electroche-
motherapy of solid organs has been evaluated in phase I and
II trials in humans. Here, ECT was conducted intraoperatively
by individually inserted long-needle electrodes and intravenous
BLM administration.32,91 A significant reduction of viable
tumor tissue in ECT-treated metastases was observed.
Infarct-like necrosis occurred presumably caused by the cyto-
toxic and vascular-disrupting effect on tumor cells and small
tumor blood vessels.22,91,96 Histopathological analysis of color-
ectal liver metastases after ECT treatment revealed necrotic
and fibrotic changes of tumor and normal tissue in the treated
area, whereas 3 months later, a regeneration was observable.
The analysis also revealed that after ECT treatment, most ves-
sels (>5 mm) and biliary structures were preserved.93 Due to
close anatomical relation of the liver to the heart, cardiac
arrhythmia can occur. Synchronized application of electrical
pulses is therefore recommended to prevent this unintended
effect.32 Internal solid organs and tissues lack the protective
barrier of the skin and possess a relatively large electrical con-
ductivity. This has to be taken into account while treatment
planning, as the electrical current delivered during ECT can
propagate through a larger volume of tissue surrounding the
treated region and might interfere with the patient’s heart func-
tion.32,97 With synchronized application of EP, minor arrhyth-
mias can occur (2.2%), so patients with epilepsy or previous
myocardial infarction should be treated with caution.26,98,99
In a small clinical trial, patients received an open approach
of ECT for the treatment of unresectable colorectal liver metas-
tases. The obtained response rates 4 weeks after ECT were 55%
as complete response and 45% stable disease.100 Additionally,
an overall and progression-free survival at 6 months of 80% to
100% was achieved by the treatment. Another study evaluated
the treatment response of HCC and concomitant Vp3-Vp4 por-
tal vein tumor thrombus (PVTT) treated by percutaneous ECT.
In 5 of 6 patients, complete necrosis of the PVTT could be
observed, as well as cases with complete tumor necrosis by
associated HCC nodules.26 These first results show the poten-
tial of percutaneous ECT in case of Vp3-Vp4 PVTT treatment.
A recently published study94 tested, in a prospective pilot study
on HCC, the effectiveness of ECT. They obtained a complete
response rate of 88% per treated lesion (lesion size: 8-41 mm)
and confirmed feasibility and safety, as no treatment or post-
operative adverse events were recorded, even in cases with
lesions located near the major hepatic vessels.
A recent study by Gasljevic et al93 demonstrates regressive
changes in the whole ECT-treated area of the liver. The
detailed histopathological evaluation of the resected tumors
in a specific group of patients who underwent 2-stage operation
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was shown. Regressive changes in ECT-treated liver metas-
tases were evaluated after the second operation (in 8 + 10
weeks) in 7 patients and 13 metastases when the treated metas-
tases were resected. The ECT was able to induce coagulation
necrosis in the treated area encompassing both tumor and a
narrow band of normal tissue. The functionality of vessel larger
than 5 mm was preserved at the time of observation, with
evidence of disruption of vessels less than 5 mm. Regenerative
changes in the peripheral parts of the treated area were seen
8+ 10 weeks after ECT. These findings are important because
it confirmed that ECT can be indicated for the therapy of
metastases near major blood vessels in the liver to provide a
safe approach with good antitumor efficacy.
Djokic et al94 reported the results of a prospective study
conducted in patients with HCC. Electrochemotherapy with
BLM was performed on 17 HCCs in 10 patients. The complete
response rate at 3 to 6 months was 80% per patient and 88% per
treated lesion. Electrochemotherapy of HCC proved to be a
feasible and safe treatment in all 10 patients. The results at
average of 20.5 months after ECT show that in 15 out of 17
lesions complete response was obtained.
The obtained response rates by ECT treatment of hepatic
lesions vary a lot. This might be caused by different sample
sizes among studies, as well as individual treatment planning.
As each lesion has a special size and structure, specific ampli-
tude calculations and probe positioning need to be planned.
Therefore, the results of the different groups can be hardly
compared, as each intervention is biased by the involved opera-
tors. Also, needle placement differs in accuracy, even with
imaging control, as some interventions are free handed and
other based on assisting systems. Another restriction is the
individual vascular structure of each hepatic lesion, which
influences the distribution of the drugs in the tumor vascular
system and extracellular space. Therefore, it is possible that big
lesions lack in a sufficient concentration of the drug, as the
distribution is insufficient or delayed at the time point of EP.
An improvement in response rates can be obtained by accurate
treatment simulations, which help to obtain correct amplitudes,
as well as real-time feedback of transmembrane voltage, which
prevents IRE or insufficient EP. Another point of improvement
is the inclusion of navigation systems to minimize manual
errors. A sufficient concentration of cytostatic drug can be
obtained by a combination of intratumoral and intravenous
injection. The successful establishment of ECT as hepatic
lesion treatment can offer an additional minimally invasive
treatment in the case of malignant lesions with decreased sys-
temic side effects.
Conclusion
Electrochemotherapy for cutaneous and subcutaneous malig-
nancies is already well established. Even if only few experi-
ences have been published for colorectal liver metastases
treated by ECT, considering the proven safety and the promis-
ing results, this treatment option deserves further attention. In
the case of malignant hepatic lesions, different therapy options
exist. A tumor resection leads to immediate absence of tumor
tissue, in contrast (thermo)ablative procedures will induce
necrotic damages whereas chemoablative procedures induce
cell apoptosis. As patients with cancer suffer from multiple
stress factors (psychical, illness, oncological treatment), a
minimally invasive procedure can relieve associated symp-
toms, while decreasing interventional caused complaints. In
contrast to chemoembolization techniques, ECT relies on
membrane nonpermeant chemotherapeutics, which need EP for
cell uptake. Improvements need to be done to achieve homo-
geneous EP in the treated area, as well as steady concentrations
of cytostatic drug in big lesions. If this can be accomplished, it
is possible that response rates achieved with ECT can exceed
those achieved with TACE. For sure, ECT can induce tumor
volume shrinkage, suggesting an implementation in clinical
routine as neoadjuvant treatment to enhance future tumor
resection.
Electrochemotherapy is usually applied in palliative set-
tings for patients with unresectable tumors, resulting in ame-
lioration of quality of life. In most cases, it is used in treatment
of advanced neoplastic lesions in which radical surgical treat-
ment is not possible (eg, due to lesion location, size, and/or
number). Electrochemotherapy allows treating tumor nodules
in the proximity of important structures like vessels and
nerves. The safety profile of ECT is favorable. Most of the
observed adverse events are local and transient, including
moderate local pain, erythema, edema, and muscle contrac-
tions during EP. No serious adverse events or deaths related to
ECT have been reported in studies conducted according to
ESOPE SOPs. Electrochemotherapy is well accepted by
patients, as indicated by the high percentage of those who
would accept retreatment, if necessary.
Treatment of nonsuperficial nodules with ECT is at its
early stages, either during laparotomy procedures or by per-
cutaneous introduction of the electrodes. However, from an
operational procedure, placement of multiple parallel electro-
des can be difficult.
Limitations of ECT are the need for interventional individ-
ual electric pulse generating systems, individual electrode nee-
dles, and complex preinterventional planning. As the success of
difficult interventions in deep-seated tumors will rely on accu-
rate needle placement, robotic navigated systems as well as
image guidance improve successful ECT treatment and mini-
mize reintervention.
Percutaneous ECT of solid organs is a novel, potentially
very effective treatment option in minimally invasive
oncologic treatments. Further trials have to be conducted
to establish best treatment algorithms (ie, strength and
length of EPs, dosage, and type of chemotherapeutic
agents) as well as to prove therapeutic efficacy for differ-
ent tumor entities.
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